Triple
T32170242
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | PMDA Japan |
E821690
|
entity |
| Predicate | instanceOf |
P0
|
FINISHED |
| Object | pharmaceutical regulatory agency |
C57190
|
CONCEPT FINISHED |
How this triple was built (1 step)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
CD
Concept disambiguation
gpt-5-mini-2025-08-07
Target class: pharmaceutical regulatory agency Context triple: [PMDA Japan, instanceOf, pharmaceutical regulatory agency]
-
A.
pharmaceutical regulatory agency
chosen
A pharmaceutical regulatory agency is a governmental or authoritative body responsible for evaluating, approving, and monitoring the safety, efficacy, quality, and marketing of medicinal products within its jurisdiction.
-
B.
pharmacy regulator
A pharmacy regulator is an authority or organization responsible for overseeing, licensing, and enforcing standards for pharmacies and pharmacists to ensure the safe, ethical, and effective use of medications.
-
C.
center of the U.S. Food and Drug Administration
The center of the U.S. Food and Drug Administration is the primary organizational unit within the FDA responsible for regulating and overseeing a specific category of products, such as drugs, biologics, or medical devices, to ensure their safety and effectiveness.
-
D.
U.S. Food and Drug Administration center
A U.S. Food and Drug Administration center is a specialized organizational unit within the FDA responsible for regulating and overseeing specific categories of products, such as drugs, biologics, medical devices, or food, to ensure their safety, effectiveness, and proper labeling.
-
E.
pharmacovigilance body
A pharmacovigilance body is an organization responsible for monitoring, assessing, and preventing adverse effects or other drug-related problems to ensure the ongoing safety and effective use of medicines.
- F. None of above.
Provenance (1 batch)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3490699a48190bbef96b198e8fade |
completed | April 30, 2026, 12:20 p.m. |
Created at: May 1, 2026, 12:33 a.m.